CAROL COVARRUBIAS: Open Payments
NPI 1972118404 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 18 payments from 9 companies in 2025. Trend: 2023 $143 · 2024 $139 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 1 | $121 |
| E.R. Squibb & Sons, L.L.C. | 4 | $107 |
| ARRAY BIOPHARMA INC | 4 | $89 |
| Daiichi Sankyo Inc. | 3 | $88 |
| Eisai Inc. | 2 | $41 |
| JAZZ PHARMACEUTICALS INC. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| Gilead Sciences, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
Products named: RYBREVANT, OPDIVO, BRAFTOVI, Enhertu, Lenvima, DATROWAY, ZEPZELCA, Trodelvy.
Industry payments across FL — which companies pay providers there.
